Search research articles
Contact Us
Filters
Showing results (111-120 of 159) with videos related to
Page
of 16
Sort By:
BMJ Open
|
August 17, 2021
Improving professional health literacy in hospitals: study protocol of a participatory codesign and implementation study
Johanna Sophie Lubasch, Mona Voigt-Barbarowicz, Sonia Lippke, et al.
International Journal of Cancer
|
March 24, 2026
Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315)
Fabian Acker, Katharina Wenger, Martin Reck, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 19, 2021
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy
Marcel Wiesweg, Cedric Preuß, Julia Roeper, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 3, 2026
Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)
Friederike C Althoff, Horst-Dieter Hummel, Konrad Kokowski, et al.
Neurology
|
February 27, 2015
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Agnieszka Korfel, Eckhard Thiel, Peter Martus, et al.
Clinical Lung Cancer
|
April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
Remi Veillon, Hiroshi Sakai, Xiuning Le, et al.
JTO Clinical and Research Reports
|
April 8, 2024
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)
Frank Griesinger, Martin Sebastian, Wolfgang M Brueckl, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 25, 2022
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany
Frank Griesinger, Maurice Pérol, Nicolas Girard, et al.
International Journal of Cancer
|
February 8, 2024
Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315)
Martin Sebastian, Wilfried E E Eberhardt, Eyck von der Heyde, et al.
BMC Cancer
|
April 17, 2026
FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) - a randomized, open-label, multicenter phase II trial protocol
Rami El Shafie, Jonas Willmann, Eleni Gkika, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 159) with videos related to
Sort By:
Page
of 16
BMJ Open
|
August 17, 2021
Improving professional health literacy in hospitals: study protocol of a participatory codesign and implementation study
Johanna Sophie Lubasch, Mona Voigt-Barbarowicz, Sonia Lippke, et al.
International Journal of Cancer
|
March 24, 2026
Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315)
Fabian Acker, Katharina Wenger, Martin Reck, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 19, 2021
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy
Marcel Wiesweg, Cedric Preuß, Julia Roeper, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 3, 2026
Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)
Friederike C Althoff, Horst-Dieter Hummel, Konrad Kokowski, et al.
Neurology
|
February 27, 2015
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Agnieszka Korfel, Eckhard Thiel, Peter Martus, et al.
Clinical Lung Cancer
|
April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
Remi Veillon, Hiroshi Sakai, Xiuning Le, et al.
JTO Clinical and Research Reports
|
April 8, 2024
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)
Frank Griesinger, Martin Sebastian, Wolfgang M Brueckl, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 25, 2022
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany
Frank Griesinger, Maurice Pérol, Nicolas Girard, et al.
International Journal of Cancer
|
February 8, 2024
Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315)
Martin Sebastian, Wilfried E E Eberhardt, Eyck von der Heyde, et al.
BMC Cancer
|
April 17, 2026
FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) - a randomized, open-label, multicenter phase II trial protocol
Rami El Shafie, Jonas Willmann, Eleni Gkika, et al.
Page
of 16